Meet the Woman Behind Dunkirk". Vanity Fair. Archived from the original on 27 August 2019 . Retrieved 16 February 2018. SYNCORP Clincare technologies (P) Ltd. (www.syncorp.in) was established in the year 2010 and we serve Pharma/Biotech companies, KPO/ BPOs with wide range of services and consulting solutions. Mene Pangalos, Executive Vice President BioPharmaceuticals R&D, AstraZeneca, said: “Acquiring CinCor supports our commitment to cardiorenal disease and further strengthens our pipeline with baxdrostat. Excess levels of aldosterone are associated with hypertension and several cardiorenal diseases, including chronic kidney disease and coronary artery disease and being able to effectively reduce this would offer a much-needed treatment option for these patients.”

SYNCORP educational trust (www.syncorp.org) is associated with the University of Mysore, offers Master Degree in Clinical Research, other Diploma Courses, PG Graduate Programs, and Professional skill development programs. Previously, Deepak held the position of Vice President, Global Data Services, and General Manager India while working at Syneos Health (previously inVentiv Health Clinical), occupied this position for 5.5 Years. Associate Vice President & Solutions Head, Life Sciences HLS LOB, while working at Wipro BPO Solutions Limited, held this role for 1.5 Years. Director Operations & Customer Leader, Life Sciences and Healthcare, while working at Tata Consultancy Services Limited, he occupied this position for 2 years. Dy. General Manager & Head ¬ Clinical Data Management, while working at Reliance Industries Limited, held this role for 4 years. Head Executive Central Laboratory and QA, while working at Clinigene International, A Biocon company, held this role for 6.5 years. Application Manager Cadila Pharmaceutical diagnostics and Analytical division held this role for 4 years. A Study of CIN-107 in Patients With Uncontrolled Hypertension Receiving 1 Antihypertensive Agent (HALO). Available from: https://www.clinicaltrials.gov/ct2/show/NCT05137002?term=cin-107&draw=2&rank=1 [Last accessed 28 Dec 2022] Prior to joining Clinigene, he served as Consultant Physician at West Wales General Hospital, Wales UK between 1996-2000. He served as Medical Director of Mallya Hospital, Bangalore between 1990-1996 and was involved from concept to completion and running of the state-of-the-art tertiary referral hospital. He trained in the UK and India in Internal Medicine and Gastroenterology at St. Bartholomew Hospital and Broadgreen Hospital Liverpool, Victoria, St Martha’s and St John’s Medical College hospitals.Dunkirk (2017)". Box Office Mojo. Archived from the original on 23 December 2017 . Retrieved 23 December 2017. A Study of CIN-107 in Adults With Primary Aldosteronism (spark-PA). Available from: https://www.clinicaltrials.gov/ct2/show/NCT04605549?term=cin-107&draw=2&rank=3 [Last accessed 28 Dec 2021] Dr. Arvind has authored several medical books and published articles in premier International medical journals such as Lancet, GUT and Gastroentology. He has also been a medical teacher and examiner both in India and the United Kingdom.

The acquisition will bolster AstraZeneca’s cardiorenal pipeline by adding CinCor’s candidate drug, baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) for blood pressure lowering in treatment-resistant hypertension. A Study to EvaluateCIN-107for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease. Available from: https://clinicaltrials.gov/ct2/show/NCT05432167?term=CIN-107&draw=2&rank=4 [Last accessed 28 Dec 2022]. By qualification Subham holds Master’s degree in Biochemistry from Bangalore University. He had won the Indian Leadership Award for Industrial Development, 2012 from All India Achiever's Foundation, New Delhi.

You want a partner that is as committed to your success as you are.

Board Member and President Syncorp Health, he brings over thirty (30) plus years of experience in Life Sciences & Health Care (LSHC) industry. Led the businesses in Strategic roles in companies like TCS LSHC, Wipro LSHC, Reliance, Biocon Ltd, Syneos Health & Cadila Pharmaceutical, experiences includes P&L leadership, building Offshoring, go-to-market strategies & Solutioning, Transitions, Transformation initiatives, & Quality Management services in Contract Research Organizations (CRO), BPO Life Sciences & Health Care (LSHC). This announcement may include statements that are not statements of historical fact, or “forward-looking statements,” including with respect to AstraZeneca’s proposed acquisition of CinCor. Such forward-looking statements include, but are not limited to, the ability of AstraZeneca and CinCor to complete the transactions contemplated by the acquisition agreement, including the parties’ ability to satisfy the conditions to the consummation of the offer contemplated thereby and the other conditions set forth in the merger agreement, statements about the expected timetable for completing the transaction, AstraZeneca’s and CinCor’s beliefs and expectations and statements about the benefits sought to be achieved in AstraZeneca’s proposed acquisition of CinCor, the potential effects of the acquisition on both AstraZeneca and CinCor, the possibility of any termination of the acquisition agreement, as well as the expected benefits and success of baxdrostat and any combination product. These statements are based upon the current beliefs and expectations of AstraZeneca’s and CinCor’s management and are subject to significant risks and uncertainties. There can be no guarantees that the conditions to the closing of the proposed transaction will be satisfied on the expected timetable or at all or that baxdrostat or any combination product will receive the necessary regulatory approvals or prove to be commercially successful if approved. If underlying assumptions prove inaccurate or risks or uncertainties materialise, actual results may differ materially from those set forth in the forward-looking statements.